Evidence map›Paper›PMID 32635350›Full record

ArticleNutrients2020

Combination Antioxidant/NSAID Therapies and Oral/Topical Ocular Delivery Modes for Prevention of Oxygen-Induced Retinopathy in a Rat Model.

Kay D Beharry, Charles L Cai, Faisal Siddiqui, Christina D'Agrosa, Anano Zangaladze, Ghassan Mustafa, Areej Qadri, Thomas J Duggan, Jacob V Aranda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kay D BeharryDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.ORCID 0000-0002-4129-475X
Charles L CaiDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Faisal SiddiquiDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Christina D'AgrosaDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Anano ZangaladzeDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Ghassan MustafaDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Areej QadriDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Thomas J DugganDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
Jacob V ArandaDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.
State University of New York · US

Funding

Synergistic Pharmacologicjntervention for Prevention of ROP (SPIPROP STUDY)U54HD071594 · NICHD · SUNY DOWNSTATE MEDICAL CENTER · PI QU, JUN · 2011 to 2015
$3.6M
Eunice Kennedy Shriver National Institute of Child Health and Human Development U54HD071594
6 · The paper itself

Abstract

Given the complexity of oxygen-induced retinopathy (OIR), we tested the hypothesis that combination therapies and modes of administration would synergistically optimize efficacy for prevention of OIR. Newborn rats were exposed to neonatal intermittent hypoxia (IH) from the first day of life (P0) until P14 during which they received: (1) oral glutathione nanoparticles (nGSH) with topical ocular phosphate buffered saline (PBS); (2) nGSH with topical ocular Acuvail (ACV); (3) oral coenzyme Q10 (CoQ10) + ACV; (4) oral omega 3 polyunsaturated fatty acids (

Indexed as

Administration, OphthalmicAdministration, OralAnimalsAnimals, NewbornAnti-Inflammatory Agents, Non-SteroidalAntioxidantsDisease Models, AnimalDrug Therapy, CombinationHypoxiaNeovascularization, PathologicOxygenRatsRats, Sprague-DawleyRetinaRetinal DiseasesRetinal VesselsAnti-Inflammatory Agents, Non-SteroidalAntioxidantsOxygencoenzyme Q10glutathione nanoparticlesinsulin-like Growth Factor-Iketorolacn-3 polyunsaturated fatty acidsneonatal intermittent hypoxiaoxygen-induced retinopathyvascular endothelial growth factor

Identifiers

PMID32635350
PMCPMC7400869
OpenAlexW3038542769

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.